Pharmacodynamic Trial, of Slow Release ASA, in Platelet Functionalism, a Long Term Treatment Period
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00501254|
Recruitment Status : Completed
First Posted : July 16, 2007
Last Update Posted : July 18, 2007
|Condition or disease||Intervention/treatment||Phase|
|Cardiovascular Disease||Drug: Slow release acetyl salicylic acid Behavioral: Antithrombotic effect||Phase 2 Phase 3|
- A large clinical trials have established the efficacy of the antiaggregant products in patients with ischemic cardiopathy, stroke and intermittent claudication.
- The acetylsalicylic acid (ASA) is the most used antiaggregant substance, nevertheless, and spite of being centenarian, it last some questions pending regarding the most appropriate dose, mechanisms of action implicated, the association with oder drugs, and the pharmaceutical fom in order to improve the efficacy and safety of the ASA.
- Some previous studies indicate that the slow release form of ASA has a different behaviour in the platelet effect in comparison with plain formulation.
- The aim of this study is to demonstrate the best antiaggregant and safety profile of a low dose of a slow release formulation in a long term treatment period of one year.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Randomised Clinical Trial, Parallel, Double Blind, to Evaluate the Influence of the ASA-SR (Slow-Release) in the Platelet Parameters and the Oxidative Status, in Patients With Coronary Disease of Chronic Evolution During 12 Months|
|Study Start Date :||February 2005|
|Study Completion Date :||February 2007|
- The evaluation of the effect of treatment with slow release ASA on the tromboxane/prostacyclin balance and its repercusion in the platelet aggregation [ Time Frame: one year ]
- Safety profile of the two different formulations of ASA (Slow Release and Normal Release) [ Time Frame: one year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00501254
|Hospital Universitario Virgen de la Victoria|
|Principal Investigator:||Eloy Rueda, MD||Hosp. Universitario Virgen de la Victoria, Málaga (Spain)|
|Principal Investigator:||José Pedro de la Cruz, MD, phD||Departamento de Farmacología y Terapéutica Clínica Facultad de Medicina, Universidad de Málaga|
|Principal Investigator:||José Antonio González Correa, MD, phD||Departamento de Farmacología y Terapéutica Clínica Facultad de Medicina, Universidad de Málaga|